Media coverage about Abeona Therapeutics (NASDAQ:ABEO) has trended somewhat positive on Friday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Abeona Therapeutics earned a news sentiment score of 0.02 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.5595236634809 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald set a $36.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a report on Tuesday. Maxim Group set a $35.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a report on Monday. HC Wainwright set a $30.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, BidaskClub raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $27.33.
Shares of Abeona Therapeutics (ABEO) opened at $14.80 on Friday. Abeona Therapeutics has a 52 week low of $4.55 and a 52 week high of $22.75. The stock has a market cap of $743.82, a P/E ratio of -22.42 and a beta of 1.30.
Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.05). Abeona Therapeutics had a negative return on equity of 24.57% and a negative net margin of 3,263.92%. The firm had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.24 million. The company’s revenue was down 16.0% on a year-over-year basis. analysts expect that Abeona Therapeutics will post -0.75 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/03/23/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-abeona-therapeutics-abeo-stock-price.html.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.